行情

CRIS

CRIS

居里
NASDAQ

实时行情|Nasdaq Last Sale

2.040
-0.050
-2.39%
交易中 15:23 10/15 EDT
开盘
2.090
昨收
2.090
最高
2.180
最低
2.040
成交量
6.77万
成交额
--
52周最高
2.900
52周最低
0.6000
市值
6,773.39万
市盈率(TTM)
-2.2346
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRIS 新闻

  • 我们为什么摆脱不了贫穷?诺贝尔经济学奖破解人类谜团
  • 新财富杂志.4小时前
  • 人,越朴素,越高贵
  • 格上理财.6小时前
  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire.10/04 21:05
  • Curis (CRIS) Presents At Cantor Healthcare Conference - Slideshow
  • Seeking Alpha - Article.10/03 18:08

更多

所属板块

生物技术和医学研究
+1.97%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

CRIS 简况

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
展开

Webull提供Curis, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。